Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical-stage biopharmaceutical company whose news flow centers on the development of DM199, a recombinant KLK1 protein candidate for preeclampsia, fetal growth restriction and acute ischemic stroke. Company updates frequently highlight progress in its clinical trials, regulatory interactions and financing activities that support these programs.
Investors following DMAC news can expect detailed reports on the Phase 2 investigator-sponsored trial of DM199 in preeclampsia, including interim data on blood pressure reduction, uterine artery blood flow and placental transfer findings. DiaMedica also issues news about the multi-part design of this trial, expansion cohorts, and plans to evaluate DM199 in women with early-onset fetal growth restriction.
Another major news theme is the ReMEDy2 Phase 2/3 trial in acute ischemic stroke, where DiaMedica provides enrollment updates and guidance on the timing of interim analyses. Regulatory milestones, such as the in-person pre-IND meeting with the U.S. Food and Drug Administration for a planned U.S. Phase 2 preeclampsia study and related non-clinical study requirements, are also covered in company press releases.
DiaMedica’s news feed additionally includes quarterly financial results, descriptions of its cash runway in relation to planned clinical studies, private placements and at-the-market offering arrangements. Corporate developments, such as participation in healthcare investor conferences, inducement equity grants and executive appointments in clinical leadership roles, appear regularly. For readers tracking DMAC, this news page offers a consolidated view of clinical, regulatory, financial and corporate announcements related to the company’s efforts in preeclampsia, fetal growth restriction and acute ischemic stroke.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced the appointment of David Wambeke as Chief Business Officer (CBO) to spearhead business development initiatives. Mr. Wambeke brings over 15 years of life sciences and investment banking experience, having previously been involved in over 100 financing transactions. He will play a crucial role as the company resumes enrollment in its ReMEDy2 trial for acute ischemic stroke (AIS).
In conjunction with his appointment, Mr. Wambeke purchased
DiaMedica Therapeutics (Nasdaq: DMAC) provided a business update and 2022 financial results, highlighting ongoing communications with the FDA regarding the clinical hold on its ReMEDy2 trial. The company completed Part 1 of an in-use study, with results indicating a proposed dose revision could prevent hypotension issues. As of December 31, 2022, DiaMedica reported cash and investments of $33.5 million, a decline from $45.1 million in 2021, primarily due to operational costs. R&D expenses decreased to $7.8 million, while G&A expenses rose to $6.2 million. Management will discuss these results in a conference call on March 29, 2023.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will announce its full-year 2022 financial results after market close on March 28, 2023. A live conference call to discuss the results and provide a business update is scheduled for March 29, 2023, at 7:00 AM Central Time. Interested parties can join the call by dialing (877) 550-1858 or via webcast. DM199, DiaMedica's lead candidate, is a recombinant KLK1 protein aimed at treating acute ischemic stroke. The webcast will be available for playback on the company's website for 12 months post-call.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical firm, announced that CEO Rick Pauls will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023. Mr. Pauls is scheduled to speak at 2:40 p.m. ET on March 15, and will also be available for one-on-one investor meetings throughout the event. DiaMedica's lead candidate, DM199, is the first synthetic form of the KLK1 protein, aiming to treat acute ischemic stroke and chronic kidney disease. Investors can contact their Oppenheimer representative to arrange meetings.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced the appointment of Tanya Lewis to its board of directors, effective March 1, 2023. With over 25 years in drug development, Ms. Lewis has a proven track record, having held leadership roles at Replimune Group and Karyopharm Therapeutics. Her experience includes overseeing the approval of several new drugs, including XPOVIO®. The board welcomed her expertise at a pivotal time for DiaMedica as they work to address the clinical hold on their ReMEDy2 AIS trial. Ms. Lewis aims to support the company’s mission of providing treatment options for stroke patients.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) provided an update on its clinical developments and financial results for Q3 2022. The FDA has maintained a clinical hold on the ReMEDy2 trial, requesting additional data regarding IV infusion materials. The company is preparing for an in-use study and plans to request a Type A FDA meeting. As of September 30, 2022, DiaMedica reported cash and investments of $36.1 million, down from $45.1 million at year-end 2021. R&D expenses decreased to $1.6 million, while G&A expenses rose to $1.5 million, reflecting increased operational support costs.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, announced that President and CEO Rick Pauls will participate in the 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022, in New York. The conference presents an opportunity for investors to schedule meetings with DiaMedica’s management through their Craig-Hallum representative. DiaMedica focuses on developing innovative treatments for neurological disorders and kidney diseases, with its lead candidate DM199 targeting acute ischemic stroke and chronic kidney disease.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that its President and CEO, Rick Pauls, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference from November 8-10, 2022, in Rancho Palos Verdes, California. Pauls is scheduled to speak on November 9, 2022, at 8:35 a.m. Eastern Time, and he will also be available for one-on-one investor meetings throughout the conference. DiaMedica focuses on developing treatments for neurological disorders and kidney diseases, with its lead candidate, DM199, targeting acute ischemic stroke and chronic kidney disease.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced the FDA has maintained the clinical hold on its ReMEDy2 Phase 2/3 trial for acute ischemic stroke treatment. This decision was due to a need for additional non-clinical data related to intravenous infusion materials. The company is preparing further in vitro studies to address FDA concerns and will request a Type A meeting for guidance. As of September 30, 2022, DiaMedica reported a cash balance of $36.1 million, reflecting a reduced cash burn of $2.3 million in Q3 2022. A conference call is scheduled for October 27, 2022, to discuss the update.
DiaMedica Therapeutics has appointed Julie VanOrsdel Daves as Senior VP of Clinical Development Operations, enhancing its leadership team as it prepares to resume enrollment in the ReMEDy2 acute ischemic stroke trial. Ms. Daves brings nearly 20 years of experience in clinical development, which includes pivotal Phase 3 programs. In connection with her appointment, she received a stock option grant for 140,000 shares at $1.47 each. DiaMedica's DM199, a recombinant form of KLK1, addresses significant medical needs in acute ischemic stroke and chronic kidney disease.